SCHEMBL22290397

SCHEMBL22290397

CC(C)(C)OC(=O)Nc1nc(-c2cccc(B3OC(C)(C)C(C)(C)O3)c2)cs1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 4/20 0.52
HDAC1 Q13547 3/20 0.52
HDAC2 Q92769 3/20 0.52
HDAC10 Q969S8 3/20 0.52
HDAC8 Q9BY41 2/20 0.52
HDAC6 Q9UBN7 1/20 0.48
NCOR2 Q9Y618 1/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
ALDH1A1 P00352 2/20 0.48
GAA P10253 1/20 0.48
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HPGD P15428 1/20 0.45
HTT P42858 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ABL1 P00519 2/20 0.45
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22290629 0.90 HDAC3 (0.51) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL30315912 0.90 HDAC3 (0.51) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL17548276 0.88 HDAC3 (0.44) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL28666317 0.85 ABL1 (0.49) MEN1KMT2AALDH1A1GAANPC1
SCHEMBL30489564 0.81 PRMT5 (0.44) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL20315230 0.81 PRMT5 (0.44) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL22290428 0.81 MEN1 (0.70) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL23704893 0.81 HDAC3 (0.43) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL30058847 0.81 HDAC3 (0.43) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL28661374 0.80 KMT2A (0.49) HDAC3HDAC1HDAC2HDAC10HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 EP disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 US disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB HDAC3 231/4885HDAC1 242/4885HDAC2 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.